| Literature DB >> 29263659 |
Jérémy B Coquart1, Olivier Le Rouzic2, Ghazi Racil3, Benoit Wallaert2, Jean-Marie Grosbois4.
Abstract
BACKGROUND: Pulmonary rehabilitation (PR) is a key treatment of chronic obstructive pulmonary disease (COPD) but studies are still needed to identify the most pertinent criteria to personalize this intervention and improve its efficacy.Entities:
Keywords: continuous positive airway pressure; long-term oxygen therapy; noninvasive ventilation; personalized medicine
Mesh:
Year: 2017 PMID: 29263659 PMCID: PMC5732556 DOI: 10.2147/COPD.S150827
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Figure 1Flow diagram of patients with chronic obstructive pulmonary disease managed by home-based PR.
Abbreviations: CPAP, continuous positive airway pressure; LTOT, long-term oxygen therapy; NE, no equipment; NIV, noninvasive ventilation; PR, pulmonary rehabilitation.
Baseline characteristics of patients according to their medical equipment
| Characteristics | Total patients | LTOT | NIV | CPAP | NE |
|---|---|---|---|---|---|
| Sample size (n) | 298 | 109 | 84 | 25 | 80 |
| Men to women ratio (n) | 199/99 | 73/36 | 56/28 | 20/5 | 50/30 |
| Age (years) | 63.8±11.0 | 64.8±11.8 | 64.9±8.8 | 64.9±11.9 | 60.7±11.2 |
| BMI (kg/m2) | 27.0±7.6 | 24.9±6.5 | 29.4±9.0 | 33.6±5.5 | 25.6±6.3 |
| FEV1 (L) | 1.117±0.536 | 0.930±0.423 | 0.962±0.464 | 1.409±0.575 | 1.380±0.563 |
| FEV1 (% theoretical value) | 40.9±17.1 | 35.0±14.9 | 34.3±14.5 | 53.0±16.1 | 49.9±16.1 |
| FVC (% theoretical value) | 66.2±20.1 | 59.9±19.8 | 60.6±18.4 | 74.7±16.6 | 75.8±18.5 |
| FEV1/FVC | 50.6±12.8 | 46.2±11.7 | 48.6±12.4 | 58.3±9.1 | 54.9±12.9 |
| Moderate airflow limitation (50%≤FEV1<80%), n (%) | 71 (23.8) | 15 (13.8) | 10 (11.9) | 12 (48.0) | 34 (42.5) |
| Severe airflow limitation (30%≤FEV1<50%), n (%) | 132 (44.3) | 48 (44.0) | 35 (41.7) | 11 (44.0) | 38 (47.5) |
| Very severe airflow limitation (FEV1<30%), n (%) | 95 (31.9) | 46 (42.2) | 39 (46.4) | 2 (8.0) | 8 (10.0) |
| TLC (% theoretical value) | 108.9±26.3 | 106.8±31.5 | 112.8±25.1 | 102.3±17.0 | 109.1±24.4 |
| Short-acting β2-agonists, n | 160 | 69 | 47 | 7 | 37 |
| Long-acting β2-agonists, n | 120 | 50 | 30 | 5 | 35 |
| Long-acting anticholinergic, n | 193 | 80 | 65 | 9 | 39 |
| Bronchodilator associated with corticosteroids, n | 145 | 58 | 40 | 11 | 36 |
| Inhaled corticosteroids, n | 46 | 21 | 17 | 3 | 5 |
| Oral corticosteroids, n | 61 | 38 | 12 | 2 | 9 |
Notes: Data shown as n, mean ± standard deviation, or n (%).
Significantly different from NE (p<0.05).
Significantly different from CPAP and NIV (p<0.05).
Significantly different from all others groups (p<0.05).
Significantly different from CPAP and NE (p<0.05).
Significantly different from CPAP (p<0.05).
Abbreviations: BMI, body mass index; CPAP, continuous positive airway pressure; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LTOT, long-term oxygen therapy; n, sample size; NE, no equipment; NIV, noninvasive ventilation; TLC, total lung capacity.
Comparison of exercise capacities, anxiety, depression and HRQoL at baseline and different times after home-based PR according to the medical equipment
| Test/questionnaire | Medical equipment | Baseline | Post PR | After 6 months | After 12 months |
|---|---|---|---|---|---|
| 10STS (seconds) | LTOT | 35.8±15.9 | 30.5±11.2 | 34.0±14.6 | 34.4±16.5 |
| NIV | 33.4±12.2 | 28.1±10.3 | 31.4±16.3 | 30.8±11.8 | |
| CPAP | 24.0±7.9 | 26.5±13.8 | 26.4±16.0 | 26.1±13.4 | |
| NE | 28.5±12.0 | 23.6±9.6 | 24.1±10.5 | 23.9±11.0 | |
| TUG (seconds) | LTOT | 13.0±10.2 | 11.6±10.2 | 11.6±6.8 | 10.8±5.5 |
| NIV | 11.3±5.0 | 10.5±9.2 | 10.7±5.7 | 10.3±4.2 | |
| CPAP | 8.9±4.6 | 8.3±4.4 | 8.5±5.9 | 8.9±7.3 | |
| NE | 9.1±4.8 | 7.4±2.9 | 7.5±3.3 | 7.5±3.8 | |
| 6MST (strokes) | LTOT | 248±138 | 315±156 | 300±174 | 342±195 |
| NIV | 269±134 | 372±159 | 343±172 | 410±137 | |
| CPAP | 432±171 | 480±209 | 486±255 | 486±247 | |
| NE | 395±155 | 444±155 | 469±173 | 486±171 | |
| HAD scale: anxiety state (/21) | LTOT | 9.7±4.6 | 8.7±4.3 | 7.8±4.4 | 8.1±4.7 |
| NIV | 9.6±4.6 | 8.8±4.1 | 8.0±4.6 | 8.3±4.7 | |
| CPAP | 10.0±4.6 | 8.1±4.4 | 8.1±5.0 | 8.4±5.3 | |
| NE | 9.6±4.5 | 8.3±4.3 | 7.3±4.3 | 7.8±4.1 | |
| HAD scale: depression state (/21) | LTOT | 8.1±4.1 | 6.7±4.3 | 6.4±4.3 | 6.8±4.7 |
| NIV | 7.9±3.9 | 6.2±3.9 | 5.9±3.6 | 5.9±4.4 | |
| CPAP | 7.2±4.4 | 5.3±4.7 | 5.1±4.7 | 4.8±3.6 | |
| NE | 6.9±4.1 | 5.4±3.7 | 4.5±3.5 | 4.9±3.7 | |
| HAD scale: global score (/42) | LTOT | 17.8±7.2 | 15.4±7.6 | 14.3±7.6 | 14.9±8.1 |
| NIV | 17.2±7.0 | 15.0±7.1 | 13.8±7.2 | 14.2±7.8 | |
| CPAP | 16.9±7.5 | 13.4±8.3 | 13.1±8.1 | 13.2±7.8 | |
| NE | 16.4±7.7 | 13.7±6.9 | 11.8±6.7 | 12.7±6.4 | |
| MRF-28 (/100) | LTOT | 56.1±20.9 | 47.9±22.0 | 45.9±21.7 | 50.0±22.4 |
| NIV | 51.7±21.8 | 44.7±23.4 | 46.3±25.7 | 43.4±25.5 | |
| CPAP | 40.3±20.6 | 35.3±24.6 | 36.9±26.1 | 32.6±26.2 | |
| NE | 40.5±23.0 | 32.7±20.8 | 26.2±18.3 | 30.0±20.9 | |
| VSRQ (/80) | LTOT | 30.3±15.5 | 37.3±16.7 | 37.6±16.5 | 34.1±14.8 |
| NIV | 32.5±13.3 | 39.5±15.7 | 39.3±16.1 | 39.3±16.7 | |
| CPAP | 31.4±14.8 | 41.1±18.3 | 38.8±16.7 | 41.5±16.8 | |
| NE | 37.2±16.5 | 42.7±16.8 | 44.9±15.5 | 43.4±15.5 | |
| VQ11 (/55) | LTOT | 36.0±8.5 | 32.4±8.8 | 30.6±8.3 | 33.3±8.9 |
| NIV | 32.9±8.4 | 30.7±10.1 | 28.8±9.5 | 28.8±11.1 | |
| CPAP | 33.0±6.8 | 29.9±10.0 | 25.9±10.5 | 27.7±7.9 | |
| NE | 31.2±9.2 | 27.1±9.4 | 25.8±8.9 | 27.2±9.5 |
Notes:
Significantly different from NE (p<0.05).
Significantly different from CPAP (p<0.05).
Significantly different compared to post PR (p<0.05).
Significantly different from all other times (p<0.05).
Significantly different compared to after 6 months (p<0.05).
Abbreviations: 6MST, 6-minute stepper test; 10STS, 10 times sit-to-stand test; CPAP, continuous positive airway pressure; HAD, Hospital Anxiety and Depression; HRQoL, health-related quality of life; LTOT, long-term oxygen therapy; MRF-28, Maugeri Foundation Respiratory Failure Questionnaire; NE, no equipment; NIV, noninvasive ventilation; PR, pulmonary rehabilitation; TUG, timed up-and-go test; VQ11, COPD-specific HRQoL Questionnaire; VSRQ, Visual Simplified Respiratory Questionnaire.
Figure 2Percentage of patients who improved their exercise capacities, anxiety, depression, and health related quality of life.
Notes: Improvement was evaluated after 2 months of home-based pulmonary rehabilitation. Results are given according to patients’ medical equipment. *p<0.05.
Abbreviations: 6MST, 6-minute stepper test; CPAP, continuous positive airway pressure; HAD, Hospital Anxiety and Depression; LTOT, long-term oxygen therapy; NE, no equipment; NIV, noninvasive ventilation; TUG, timed up-and-go test; VSRQ, Visual Simplified Respiratory Questionnaire.